Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors.

Tolcher AW, Papadopoulos KP, Patnaik A, Wilson K, Thayer S, Zanghi J, Gemo AT, Kavanaugh WM, Keer HN, LoRusso PM.

Ann Oncol. 2016 Mar;27(3):526-32. doi: 10.1093/annonc/mdv591. Epub 2015 Dec 8.

PMID:
26646757
2.

ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2.

Kalashnikova EV, Revenko AS, Gemo AT, Andrews NP, Tepper CG, Zou JX, Cardiff RD, Borowsky AD, Chen HW.

Cancer Res. 2010 Nov 15;70(22):9402-12. doi: 10.1158/0008-5472.CAN-10-1199. Epub 2010 Sep 23.

3.

Chromatin loading of E2F-MLL complex by cancer-associated coregulator ANCCA via reading a specific histone mark.

Revenko AS, Kalashnikova EV, Gemo AT, Zou JX, Chen HW.

Mol Cell Biol. 2010 Nov;30(22):5260-72. doi: 10.1128/MCB.00484-10. Epub 2010 Sep 20.

4.

Androgen-induced coactivator ANCCA mediates specific androgen receptor signaling in prostate cancer.

Zou JX, Guo L, Revenko AS, Tepper CG, Gemo AT, Kung HJ, Chen HW.

Cancer Res. 2009 Apr 15;69(8):3339-46. doi: 10.1158/0008-5472.CAN-08-3440. Epub 2009 Mar 24.

5.

ANCCA, an estrogen-regulated AAA+ ATPase coactivator for ERalpha, is required for coregulator occupancy and chromatin modification.

Zou JX, Revenko AS, Li LB, Gemo AT, Chen HW.

Proc Natl Acad Sci U S A. 2007 Nov 13;104(46):18067-72. Epub 2007 Nov 12.

Supplemental Content

Support Center